Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections
AssigneeYale University
InventorsYung-chi Cheng, Hiromichi Tanaka, Masanori Baba
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel compounds according to the general formulas I, II, III, IV or V: wherein B is nucleoside base according to the structure: and the remaining variables as defined in the specification, and pharmaceutical compositions comprising the compounds. The compounds are useful interalia as anti-viral agents in viral therapy.
Claims42
A compound according to the formula I, II, III, IV or V:
- wherein B is nucleoside base according to the structure:
- R is H, F, Cl, Br, I, C1-C4 alkyl, —C≡N, —C≡C—Ra,
- X is H, C1-C4 alkyl (preferably, CH3), F, Cl, Br or I;
- Z is O or CH2, with the proviso that Z is CH2 and not O when the compound is according to general formula II, R3 is —C≡C—H and R2 is H or a phosphate, diphosphate, triphosphate or phosphotriester group;
- R1 is H, an acyl group, a C11-C20 alkyl or an ether group;
- R2 is H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group or a
- group;
- Nu is a radical of a biologically active antiviral compound such that an amino group or hydroxyl group from said biologically active antiviral compound forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety;
- R8 is a C1-C20 alkyl or ether group;
- k is 0-12, preferably, 0-2;
- R3 is selected from a C1-C4 alkyl (preferably, CH3), —(CH2)n—C≡C—Ra,
- with the proviso that R3 of compound formula II is not a —C≡C—H group when Z is O and R2 is H, a phosphate, diphosphate, triphosphate or phosphodiester;
- R3a and R3b are independently selected from H, F, Cl, Br or I;
- R4 and R5 are independently selected from H, F, Cl, Br, I, OH, C1-C4 alkyl (preferably, CH3), —(CH2)n—C≡C—Ra,
- with the proviso that R4 and R5 are not both H;
- Ra is H, F, Cl, Br, I, or —C1-C4 alkyl, preferably H or CH3;
- Y is H, F, Cl, Br, I or —C1-C4 alkyl, preferably H or CH3;
- and
- n is 0, 1, 2, 3, 4 or 5, preferably 0, 1 or 2;
- and their anomers, pharmaceutically acceptable salts, solvates, or polymorphs thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-53. (canceled)
Dependencies are inferred from the claim text.